Combining several screening tests: optimality of the risk score.
about
Classification and selection of biomarkers in genomic data using LASSO.A Chronic Fatigue Syndrome - related proteome in human cerebrospinal fluid.Estimation of diagnostic test accuracy without full verification: a review of latent class methodsThe Net Reclassification Index (NRI): a Misleading Measure of Prediction Improvement Even with Independent Test Data SetsOn the analysis of glycomics mass spectrometry data via the regularized area under the ROC curveEstimating time-dependent ROC curves using data under prevalent sampling.Assessing lead time of selected ovarian cancer biomarkers: a nested case-control studyNext-generation stool DNA test accurately detects colorectal cancer and large adenomasA boosting method for maximizing the partial area under the ROC curve.Robust prediction of t-year survival with data from multiple studies.A unifying framework for evaluating the predictive power of genetic variants based on the level of heritability explained.Neuropathology-based risk scoring for dementia diagnosis in the elderly.Measures of prediction error for survival data with longitudinal covariates.Homogeneity tests of clustered diagnostic markers with applications to the BioCycle Study.A non-parametric method for building predictive genetic tests on high-dimensional data.Impact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma.Development of a symptom score for clinical studies to identify children with a documented viral upper respiratory tract infection.Integrating the predictiveness of a marker with its performance as a classifierCombination of longitudinal biomarkers in predicting binary events.Using the optimal robust receiver operating characteristic (ROC) curve for predictive genetic tests.PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.Classification versus association models: should the same methods apply?Peritoneal carcinomatosis from ovarian cancer: chemosensitivity test and tissue markers as predictors of response to chemotherapy.Luteinizing hormone, testosterone and inhibin B levels in the peripubertal period and racial/ethnic differences among boys aged 6-11 years: analyses from NHANES III, 1988-1994.A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials.Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective.Risk Classification with an Adaptive Naive Bayes Kernel Machine Model.Two-stage biomarker panel study and estimation allowing early termination for futilityBacterial Loads Measured by the Xpert MTB/RIF Assay as Markers of Culture Conversion and Bacteriological Cure in Pulmonary TB.Assessing treatment-selection markers using a potential outcomes framework.A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantationUse of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infeEvaluating markers for the early detection of cancer: overview of study designs and methods.Evaluating the improvement in diagnostic utility from adding new predictors.Bivariate marker measurements and ROC analysis.A serial risk score approach to disease classification that accounts for accuracy and cost.Testing for improvement in prediction model performance.Subgroup specific incremental value of new markers for risk prediction.Joint modeling, covariate adjustment, and interaction: contrasting notions in risk prediction models and risk prediction performancePrediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.
P2860
Q24811716-1330EEE0-4AD5-4C1D-80EC-80A089DDDD0EQ25256334-11CEEE63-01C5-4907-A7A7-B931C488D8E5Q28654651-78755FF1-FAEF-4A0E-A42E-98DD9C0A2EEAQ31011669-E56E2138-A66E-4B51-B00F-FAEAB3ECE2A9Q31139869-D34F065D-C1DD-4373-B728-BDB37C9A7D28Q31144995-429F674D-AA23-4A49-A89D-97B9344435BFQ33574039-00157C4A-2313-4593-9473-62061AACC5B7Q33598163-6F1EBB30-7684-4855-BA33-478595DDFBBFQ33600292-0275B1BD-CC0D-4519-9B77-B07AAC153E15Q33644852-021602C2-EF36-4CE7-9806-44E416CED59DQ33769562-47018F0C-C477-407D-B238-F66113780545Q33780675-9690A325-F3E1-41C5-84FF-DA6FDB51903CQ33817175-B8E9AD8E-17F1-4DAF-978D-1AD1B042EC3EQ33855892-26FA8A89-7964-4539-BDD2-13786E526C7DQ33967840-DC44B853-C7F4-4E48-BFEC-16A1475A5647Q33988224-F2AAEBE8-23F4-413B-8BD9-8FEF152507F5Q34067095-92C184B7-6451-47B1-B7DF-A4571E6AE2E9Q34129175-DBAA2340-EC42-495C-97BF-334454EA688AQ34209145-67CF6BD6-FDD2-4924-B023-A49EC47C823FQ34577794-18473FFE-FA61-4617-92C2-91A8FA219E36Q34914187-95C579CA-8F05-45D4-9711-EE80F85A4225Q35118255-B821EAC8-9622-44E0-8707-E9FC1B0FE663Q35121648-8FCA9E97-6EA4-4B45-BC36-7645FA2600E9Q35202562-6DE0ACEC-0A97-4482-A33B-FA686E7C2044Q35681400-F9C52EAF-71C3-4C76-8BA0-39D901B3A4A1Q35873702-4945B191-391D-4CED-BF4E-13E4B05C5076Q35902754-54AEF30A-3B1B-4EAE-B6C8-CFC285C736BCQ36061690-A9FFD7A5-1B14-4558-85C0-6A19F69B0B1AQ36100081-C5C3903F-BB87-4FBE-A954-50CB7086F529Q36157844-0B5CA5F4-29F2-47D8-B7E4-7E7D9FCC8541Q36162053-9F08F1B0-9996-4364-9C42-4FEE08F1FD90Q36392555-EA95B38E-417E-497D-BDB6-1C7AA6EF373BQ36421984-703320D7-BB82-4539-9995-C9EBD87CD222Q36452671-72778E95-C7A6-4CFF-8481-F0D560EFDA8FQ36489979-7A2E40D9-2872-4159-94B9-73FC36499DA6Q36683821-24806FB6-E3DF-4E43-A0DB-0804644CFF88Q36763246-8ED156D6-214B-422A-AC79-42AADE905210Q36788462-4A6CC88F-FB99-4A24-AD25-BF4024AAE161Q36862689-4A4F84BD-E122-4586-9224-0871D12263C2Q36936018-7B6D6141-9B0A-4169-AF1B-BC22A681DA8B
P2860
Combining several screening tests: optimality of the risk score.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Combining several screening tests: optimality of the risk score.
@en
Combining several screening tests: optimality of the risk score.
@nl
type
label
Combining several screening tests: optimality of the risk score.
@en
Combining several screening tests: optimality of the risk score.
@nl
prefLabel
Combining several screening tests: optimality of the risk score.
@en
Combining several screening tests: optimality of the risk score.
@nl
P1433
P1476
Combining several screening tests: optimality of the risk score.
@en
P2093
Margaret Sullivan Pepe
Martin W McIntosh
P304
P356
10.1111/J.0006-341X.2002.00657.X
P407
P577
2002-09-01T00:00:00Z